Kancera Balance Sheet Health

Financial Health criteria checks 6/6

Kancera has a total shareholder equity of SEK83.0M and total debt of SEK0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are SEK95.6M and SEK12.6M respectively.

Key information

Debt to equity ratio

SEK 0

Debt

Interest coverage ratio	n/a
Cash	SEK 75.70m
Equity	SEK 83.00m
Total liabilities	SEK 12.64m
Total assets	SEK 95.64m

Recent financial health updates

Recent updates

Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth

Aug 13

We Think Kancera (STO:KAN) Needs To Drive Business Growth Carefully

Dec 06

Is Kancera (STO:KAN) In A Good Position To Deliver On Growth Plans?

Jul 19

Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth

Mar 08

We Think Kancera (STO:KAN) Can Afford To Drive Business Growth

Jun 29

We're Hopeful That Kancera (STO:KAN) Will Use Its Cash Wisely

Mar 08

Here's Why We're Watching Kancera's (STO:KAN) Cash Burn Situation

Aug 02

We're Not Very Worried About Kancera's (STO:KAN) Cash Burn Rate

Apr 06

Here's Why We're Not Too Worried About Kancera's (STO:KAN) Cash Burn Situation

Dec 21

Financial Position Analysis

Short Term Liabilities: KAN's short term assets (SEK77.6M) exceed its short term liabilities (SEK12.6M).

Long Term Liabilities: KAN has no long term liabilities.

Debt to Equity History and Analysis

Debt Level: KAN is debt free.

Reducing Debt: KAN has no debt compared to 5 years ago when its debt to equity ratio was 44.4%.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: KAN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: KAN has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 5.2% each year.

Kancera Balance Sheet Health

Financial Health criteria checks 6/6

Key information

Recent financial health updates

Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth

We Think Kancera (STO:KAN) Needs To Drive Business Growth Carefully

Is Kancera (STO:KAN) In A Good Position To Deliver On Growth Plans?

Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth

We Think Kancera (STO:KAN) Can Afford To Drive Business Growth

We're Hopeful That Kancera (STO:KAN) Will Use Its Cash Wisely

Recent updates

Kancera AB (Publ) Provides Operational Update Concerning Its Clinical Development Program

New minor risk - Share price stability

Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth

Kancera AB's Fractal Study Results to Be Presented at the ESC 2024 Conference

New major risk - Financial position

Kancera AB (publ) Announces Executive Changes

Kancera AB (publ) Reports Positive Results from the Clinical Phase I Study with KAND145 in Healthy Subjects

New major risk - Shareholder dilution

Forecast breakeven date pushed back to 2025

Kancera AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 73.011989 million.

New major risk - Financial position

New major risk - Share price stability

Kancera AB (publ) Reports Positive Top Line Results from the FRACTAL Study

We Think Kancera (STO:KAN) Needs To Drive Business Growth Carefully

Forecast breakeven date moved forward to 2024

Kancera AB (publ), Annual General Meeting, May 27, 2024

Kancera AB (publ) Receives Finnish Regulatory Agency Approval for Phase I Study of KAND145

Kancera AB (publ) Appoints Markus Jerling as Chief Medical Officer

Kancera AB (publ) to Report Q3, 2023 Results on Nov 17, 2023

New major risk - Share price stability

Kancera AB (Publ) Announces Newly Published Research Publication Confirms the Potential for Kancera's Fractalkine Blocker KAND567 in Cardiovascular Disease

Is Kancera (STO:KAN) In A Good Position To Deliver On Growth Plans?

New minor risk - Share price stability

Kancera AB (publ) Reports Dosing of First Patient in the KANDOVA Study

Kancera AB (publ) Appoints Peter Selin as New Chief Executive Officer, Effective from July 1 2023

Independent Director recently sold kr58k worth of stock

Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth

Forecast to breakeven in 2025

Kancera AB (publ) Submits Regulatory Application to the Swedish Medical Products Agency to Conduct Clinical Studies of KAND567 in Ovarian Cancer

Insufficient new directors

Kancera AB (publ) Reports New Preclinical Results Supporting Potential for Its Ror1 Inhibitor in B-Cell Malignancies

Kancera AB (publ) Reports Promising Preclinical Results from Studies of Its Fractalkine Axis Blocking Drug Candidates in B-Cell Lymphoma

Kancera AB (publ) Reports Good Progress of Recruitment in Ongoing Phase IIa Study of Kand567 in Myocardial Infarction and the Decision to Allow for Recruitment of Additional Patients

Kancera AB (publ) Reports Convincing Preclinical Results and Decision to Initiate Clinical Development of KAND567 in Ovarian Cancer

We Think Kancera (STO:KAN) Can Afford To Drive Business Growth

Insufficient new directors

We're Hopeful That Kancera (STO:KAN) Will Use Its Cash Wisely

Insufficient new directors

Here's Why We're Watching Kancera's (STO:KAN) Cash Burn Situation

First quarter 2021 earnings released: kr0.029 loss per share (vs kr0.56 loss in 1Q 2020)

Insider recently bought kr65k worth of stock

We're Not Very Worried About Kancera's (STO:KAN) Cash Burn Rate

Full year 2020 earnings released: kr0.13 loss per share (vs kr0.18 loss in FY 2019)

New 90-day low: kr1.62

Here's Why We're Not Too Worried About Kancera's (STO:KAN) Cash Burn Situation

New 90-day low: kr2.23

New 90-day low: kr2.37

Kancera AB (publ) to Report Q3, 2021 Results on Nov 19, 2021

New 90-day high: kr3.98

First half earnings released

New 90-day high - kr2.96

Oncopeptides AB (publ) (OM:ONCO) agreed to acquire Kancera's drug development facility in Solna, Sweden.

Financial Position Analysis

Debt to Equity History and Analysis

Balance Sheet

Cash Runway Analysis

Discover healthy companies